

Undecaprenyl Pyrophosphate Involvement in Susceptibility of *Bacillus subtilis* to Rare Earth Elements

Takashi Inaoka^a and Kozo Ochi^b

National Food Research Institute-National Agriculture Research Organization, Tsukuba, Ibaraki, Japan,^a and Department of Life Science, Hiroshima Institute of Technology, Saeki-ku, Hiroshima, Japan^b

The rare earth element scandium has weak antibacterial potency. We identified a mutation responsible for a scandium-resistant phenotype in *Bacillus subtilis*. This mutation was found within the *uppS* gene, which encodes undecaprenyl pyrophosphate synthase, and designated *uppS86* (for the Thr-to-Ile amino acid substitution at residue 86 of undecaprenyl pyrophosphate synthase). The *uppS86* mutation also gave rise to increased resistance to bacitracin, which prevents cell wall synthesis by inhibiting the dephosphorylation of undecaprenyl pyrophosphate, in addition to enhanced amylase production. Conversely, overexpression of the wild-type *uppS* gene resulted in increased susceptibilities to both scandium and bacitracin. Moreover, the mutant lacking undecaprenyl pyrophosphate phosphatase (BcrC) showed increased susceptibility to all rare earth elements tested. These results suggest that the accumulation of undecaprenyl pyrophosphate renders cells more susceptible to rare earth elements. The availability of undecaprenyl pyrophosphate may be an important determinant for susceptibility to rare earth elements, such as scandium.

Rare earth elements consist of 17 elements, including scandium, yttrium, and the lanthanides (15 elements from lanthanum to lutetium in the periodic table). As rare earth elements have useful physical and chemical properties, these elements are of considerable importance in various industries. Although there have been many studies concerning their useful features, little is known about their biological effects in living cells. We recently reported that rare earth elements, especially scandium, activate secondary metabolism and extracellular enzyme production in certain microorganisms (12, 15, 31). In the Gram-positive model bacterium *Bacillus subtilis*, the addition of scandium to the growth medium stimulates production of an extracellular enzyme, amylase, and the dipeptide antibiotic, bacilysin (12). This effect was found to be exerted at the transcriptional level during the late stationary growth phase. These previous results suggest that the rare earth elements (especially scandium) have remarkable biological effects on microorganisms.

Rare earth elements have long been known to have weak antimicrobial potency. For example, lanthanum has been reported to inhibit the growth of *Streptococcus faecalis* due to depletion of phosphate from the medium (34). It has also been reported that scandium and indium complexes of enterochelin have bacteriostatic effects on both *Klebsiella pneumoniae* (25) and *Escherichia coli* (26). However, there have been no reports addressing mutations conferring rare earth element resistance. In the present study, we isolated a scandium-resistant *B. subtilis* mutant and successfully identified the mutation responsible for its phenotype. The results presented here suggest that undecaprenyl pyrophosphate (C₅₅-PP) is involved in susceptibility to rare earth elements, including scandium. This is the first report describing a key molecule involved in rare earth element susceptibility.

MATERIALS AND METHODS

Bacterial strains and growth conditions. The bacterial strains used in this study are listed in Table 1. The spontaneous scandium-resistant mutant SC26 was derived from *B. subtilis* strain 168. L medium (10 g of tryptone, 5 g of yeast extract, and 5 g of NaCl per liter) and NG medium (10 g of

nutrient broth, 10 g of glucose, 2 g of NaCl, 5 mg of CuSO₄ · 5H₂O, 7.5 mg of FeSO₄ · 7H₂O, 3.6 mg of MnSO₄ · 5H₂O, 15 mg of CaCl₂ · 2H₂O, and 9 mg of ZnSO₄ · 7H₂O per liter) were used in this study. Scandium chloride (ScCl₃ · 6H₂O; purity, 99.9%) and other rare earth elements (all chloride salts) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Erythromycin (0.5 µg/ml), neomycin (3 µg/ml), and chloramphenicol (4 µg/ml) were used for selection of *B. subtilis* transformants. Ampicillin (100 µg/ml) was used for selection of *E. coli* transformants.

Plasmids and DNA procedures. Oligonucleotides used for PCR are listed in Table 2. To disrupt the *yufQ* gene in *B. subtilis*, the DNA fragment containing a partial *yufQ* gene was amplified using the primers HindIII-yufQF and BamHI-yufQR, digested with HindIII and BamHI, and cloned into the corresponding sites of pMutinT3 (19). The resulting plasmid, pMutinT3-yufQ, was used for transformation of *B. subtilis* 168 with selection for erythromycin resistance, generating the strain TI367 (*yufQ*::pMutinT3).

The amino acid auxotrophic marker genes, *hisC* and *trpC*, are cotransformed at high frequency (approximately 70%). Utilizing these selectable markers, the strains TI391 (*yufQ38*) (where *yufQ38* refers to the Asn-to-Asp amino acid substitution at residue 38 of YufQ protein encoded by *yufQ*) and TI392 (*uppS86*) (where *uppS86* refers to the Thr-to-Ile amino acid substitution at residue 86 of undecaprenyl pyrophosphate synthase encoded by *uppS*) were obtained as follows. To yield the strain TI391, the histidine auxotrophic recipient strain TI389 (*hisC101 yufQ*::pMutinT3) was constructed by transforming chromosomal DNA from TI367 into strain YO-005, followed by selection for erythromycin resistance. The resulting recipient strain TI389 was transformed with genomic DNA of SC26 with selection for histidine prototrophy. Of 100 His⁺ Trp⁻ transformants, several erythromycin-sensitive transformants were selected. It was confirmed by DNA sequencing analysis that all erythromycin-sensitive transformants contained the expected *yufQ38* mutation. One of these transformants was designated TI391. To generate TI392 (*uppS86*), the

Received 27 June 2012 Accepted 8 August 2012

Published ahead of print 17 August 2012

Address correspondence to Takashi Inaoka, tina2672@affrc.go.jp.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JB.01147-12

TABLE 1 Strains used in this study

Strain	Genotype	Source or reference
168	<i>trpC2</i>	Laboratory stock
YO-005	<i>hisC101</i>	11
SC26	<i>trpC2 yufQ38 uppS86 Sc^r</i>	This study
TI367	<i>trpC2 yufQ::pMutinT3</i>	This study
TI389	<i>hisC101 yufQ::pMutinT3</i>	This study
TI391	<i>trpC2 yufQ38</i>	This study
TI392	<i>trpC2 uppS86</i>	This study
TI393	<i>trpC2 bcrC::pMutinT3</i>	This study
TI403	<i>trpC2 ΔyubB::neo</i>	This study
TI408	<i>trpC2 uppS::pHASH120 (P_{S10}-uppS)</i>	This study
TI409	<i>trpC2 yubB::pHASH120 (P_{S10}-yubB)</i>	This study

recipient strain YO-005 was transformed with genomic DNA of SC26 with selection for histidine prototrophy. Of 100 His⁺ Trp⁻ transformants, scandium-resistant transformants were selected. DNA sequencing analysis showed that all scandium-resistant transformants carried the *uppS86* mutation. One of these transformants was designated TI392. To generate TI393 (*bcrC::pMutinT3*), the DNA fragment containing a partial coding region of the *bcrC* gene was amplified using the primers HindIII-bcrCF and BamHI-bcrCR, digested with HindIII and BamHI, and cloned into the corresponding sites of pMutinT3. The resulting plasmid, pMutinT3-*bcrC*, was used for transformation with selection for erythromycin resistance.

To disrupt the *yubB* gene, the DNA fragment containing a partial *yubB* gene was amplified using the primers yubB-F and yubB-R. The amplified DNA was cloned into pCR2.1 (Invitrogen, Carlsbad, CA), generating pCR2.1-*yubB*. The neomycin resistance cassette derived from pBEST501 (14) was inserted into the region between SspI sites within the *yubB* gene on pCR2.1-*yubB*. The resulting plasmid, pCR2.1-*ΔyubB::neo*, was linearized with HindIII and transformed into *B. subtilis* 168 with selection for neomycin resistance, generating the strain TI403 (*ΔyubB::neo*).

For overexpression of *uppS*, the 456-bp fragment encoding the N-terminal part of UppS was synthesized by PCR with the primers pHASH120-*uppSF* and pHASH120-*uppSR* and cloned into the EcoRV site of pHASH120 by the TA cloning method as described by Ohashi et al. (21), resulting in pHASH120-*uppS*. For overexpression of *yubB*, the 452-bp fragment encoding the N-terminal part of YubB was amplified by PCR with primers pHASH120-*yubBF* and pHASH120-*yubBR* and cloned into pHASH120, resulting in pHASH120-*yubB*. The resulting plasmids, pHASH120-*uppS* and pHASH120-*yubB*, were used for transformation of *B. subtilis* 168 with selection for chloramphenicol resistance, creating the strains TI408 (P_{S10}-*uppS*) and TI409 (P_{S10}-*yubB*), in which the promoter of *uppS* or *yubB* has been replaced by the S10 promoter (P_{S10}).

RT-qPCR. Cells were grown in L medium at 37°C until the optical density at 650 nm (OD₆₅₀) reached 0.5 (exponential growth phase). Then, the total RNAs were prepared as described previously (13). A PrimeScript RT reagent kit with a genomic DNA (gDNA) Eraser (TaKaRa Bio Inc., Otsu, Japan) was used for the reverse transcriptase reaction according to the manufacturer's instructions. Samples were analyzed using a 7300 real-time PCR system and Thunder Bird SYBR qPCR Mix (Toyobo, Osaka, Japan). Amplification of the 16S rRNA gene was used as an internal control. Oligonucleotides used for reverse transcription-quantitative PCR (RT-qPCR) are listed in Table 2.

Determination of susceptibility to rare earth elements and bacitracin. Cells were grown in L medium at 37°C for 4 h (approximately 5 × 10⁸ cells/ml) and appropriately diluted with distilled water. Then, aliquots of 2 μl of the cell suspension were spotted onto half-strength solid L medium (agar concentration, 1.5%) containing each rare earth element at various

TABLE 2 Oligonucleotides used in this study

Primer	Oligonucleotide sequence (5' → 3') ^a
HindIII-yufQ F	CCCAAGCTTGTCCCTGCCACACTCG
BamHI-yufQ R	CGCGGATCCGCTGACTGTCTGGTCC
HindIII-bcrC F	CCCAAGCTTGTGCGCTATGCCCTATCC
BamHI-bcrC R	CGCGGATCCCAAAAATGACAAGCGGC
yubB-F	CGGTTGCCAAAGTCATTACG
yubB-R	GCCTTAAGAAGAAACGGACG
pHASH120- <i>uppSF</i>	ATGCTCAACATACTCAAAAATTGGAAG
pHASH120- <i>uppSR</i>	GATCATTCCGTCGTTTTGCG
pHASH120- <i>yubBF</i>	ATGACTCTATGGGAATTGTTGTAGC
pHASH120- <i>yubBR</i>	GTGTCTGTCGCTGTTTTCCG
RT-qPCR 16S-F	ATCTTCCGCAATGGACGA
RT-qPCR 16S-R	GCCGTGGCTTTCTGGTTA
RT-qPCR <i>uppS</i> -F	CAAACCTGCGGCTTCCAAC
RT-qPCR <i>uppS</i> -R	CGGCCATTTCCATCCATG
RT-qPCR <i>bcrC</i> -F	ATACGCAGGCATCACAGG
RT-qPCR <i>bcrC</i> -R	CACCTGTCTGATGGTCCAC
RT-qPCR <i>yubB</i> -F	AAATTGCCGTCGGACTCG
RT-qPCR <i>yubB</i> -R	GACCCAGTCAGCAAAAAGC

^a HindIII and BamHI restriction sites are underlined.

concentrations, followed by incubation at 37°C for 18 h. To determine bacitracin susceptibility, aliquots of 2 μl of cell suspension were spotted onto solid L medium containing ZnSO₄ (40 μg/ml) and bacitracin (80 or 100 μg/ml). Bacitracin (71,100 IU/g) was purchased from Nacalai Tesque (Kyoto, Japan).

Amylase assay. *B. subtilis* strains were grown in NG medium at 30°C with vigorous shaking. Amylase activity was measured as described previously (12).

RESULTS

Isolation of mutants resistant to scandium. *B. subtilis* cells were more susceptible to scandium than to other rare earth elements. In addition, we found that the scandium resistance was dependent on the growth conditions. The MIC of scandium (ScCl₃ · 6H₂O) on half-strength L agar medium was approximately 2-fold lower (i.e., increased susceptibility) than that on full-strength L medium (data not shown). We therefore used half-strength L medium for determination of *B. subtilis* susceptibility to rare earth elements. The MIC value of scandium was 300 μg/ml, whereas MICs of other rare earth elements were in the range of 500 to 800 μg/ml. To understand the physiological action of scandium, we isolated a number of scandium-resistant mutants that had developed spontaneously on half-strength L agar plates containing 300 μg/ml of scandium. All mutants (we tested 100 mutants) had only a slight resistance to scandium (MIC of 350 μg/ml). As addition of scandium to the growth medium stimulates amylase production in *B. subtilis* (12), we examined whether a scandium resistance mutation also activates amylase production. Of 30 mutants tested for their capability to produce amylase, one scandium-resistant mutant strain (SC26) showed enhanced amylase production. Therefore, we further characterized this mutant. The SC26 mutant grew normally in NG medium and sporulated well in sporulation medium (data not shown). The amylase activity in the culture broth of this mutant was approximately 2-fold higher than that in its parent strain 168 (data not shown). We previously reported that the expression level of the amylase-coding gene *amyE* in cells grown in scandium-supplemented medium was 2.3-fold higher than levels in cells grown in scandium-free medium, eventually leading to amylase overproduction (12). RT-qPCR analysis, how-




FIG 1 Scandium susceptibility of *B. subtilis* mutants. *B. subtilis* strains 168 (wild type), SC26 (scandium-resistant mutant), and a transformant TI392 (*uppS86*) were grown in L medium at 37°C for 4 h. Cells (approximately 5×10^8 cells/ml) were appropriately diluted with distilled water. Then, aliquots of 2 μ l of cell suspension were spotted onto the scandium-free (–) and scandium-containing (+) (320 μ g/ml of $\text{ScCl}_3 \cdot 6\text{H}_2\text{O}$) medium, followed by incubation at 37°C for 18 h.

ever, revealed no significant difference in the levels of *amyE* expression between the mutant SC26 and 168 (data not shown), suggesting that the effect of the scandium resistance mutation on amylase overproduction was exerted at the posttranscriptional level. Unlike amylase production, extracellular protease and antibiotic bacilysin were produced at the same levels in the SC26 mutant as in its parent strain 168 (data not shown).

Identification of a scandium resistance mutation. To identify the mutation conferring scandium resistance in the mutant SC26, we performed microarray-based mutation mapping analysis (Roche NimbleGen) and DNA sequencing. The results successfully identified two mutations at different loci in the SC26 genome: a single base substitution (112A to G, designated *yufQ38*) within the *yufQ* gene, which encodes an uncharacterized protein; and a single base substitution (257C to T, designated *uppS86*) within the *uppS* gene, which encodes an undecaprenyl pyrophosphate synthase (UppS). To investigate the possible roles of these gene products in scandium resistance, we attempted to disrupt each gene by insertional mutagenesis with the plasmid pMutinT3. Disruption of the *yufQ* gene affected neither scandium resistance nor amylase production (data not shown). Attempts to disrupt the *uppS* gene were unsuccessful, suggesting that the *uppS* gene is essential. In fact, the *uppS* gene has been reported to be essential in *Streptococcus pneumoniae* (1). To confirm the causal relationship between the identified mutations and scandium resistance, we constructed the strains TI391 (*yufQ38*) and TI392 (*uppS86*) by transformation using a histidine auxotrophic marker (see Materials and Methods). Similar to the original mutant SC26, the *uppS86* transformant showed increased resistance to scandium (Fig. 1), while the *yufQ38* transformant did not (data not shown). Furthermore, the levels of amylase production by the *uppS86* transformant TI392, as well as SC26, were approximately 2-fold greater than the level in the wild-type strain (Table 3), whereas the *yufQ38* transformant showed no effect on amylase production (data not shown). These results indicate that the *uppS86* mutation

TABLE 3 Amylase production by various mutant strains

Strain	Amylase production ^a
168 (wt) ^b	1.99 \pm 0.26
TI392 (<i>uppS86</i>)	3.36 \pm 0.42*
TI408 (P _{S10} - <i>uppS</i>)	2.48 \pm 0.53
TI403 (<i>yubB</i>)	2.88 \pm 0.48*
TI409 (P _{S10} - <i>yubB</i>)	2.12 \pm 0.32
TI393 (<i>bcrC</i>)	2.73 \pm 0.45*

^a *B. subtilis* strains were grown in NG medium at 30°C. After 72 h of cultivation, the culture supernatant obtained after centrifugation was used for amylase assay. Amylase production is expressed as amylase activity (units) as described previously (12). The asterisks denote significant differences ($P < 0.05$).

^b wt, wild type.

(but not the *yufQ38* mutation) was responsible for both increased scandium resistance and enhanced amylase production. Although other scandium-resistant mutants without amylase overproduction (10 strains were tested) also had the same level of scandium resistance as the SC26 mutant, these mutants had no mutation in the *uppS* gene (data not shown). Unexpectedly, the enhanced amylase production in the scandium-resistant *uppS86* mutant was no longer increased by addition of scandium to the culture medium (data not shown).

Undecaprenyl pyrophosphate participates in the scandium susceptibility. C₅₅-PP is the precursor for the carrier lipid, undecaprenyl phosphate (C₅₅-P), which is required for cell wall synthesis (5). C₅₅-PP synthase catalyzes eight consecutive condensation reactions of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to form C₅₅-PP (1). Bacitracin, a mixture of related cyclic peptide antibiotics, binds to C₅₅-PP in the presence of divalent cations such as Zn²⁺ and prevents the dephosphorylation of C₅₅-PP (28, 29). In *E. coli*, the overproduction of C₅₅-PP phosphatase, BacA, accelerates the conversion of C₅₅-PP to C₅₅-P, resulting in an increase in cellular resistance to bacitracin (8). Accordingly, the bacitracin susceptibilities of the *uppS86* mutants were compared to those of the parent strain in the presence of Zn²⁺ (Fig. 2). As expected, both of the *uppS86* mutant strains (SC26 and TI392) showed cross-resistance to bacitracin, suggesting that the *uppS86* mutation affects the available pool size of C₅₅-PP. To further investigate the involvement of C₅₅-PP in scandium resistance, we constructed a strain overexpressing *uppS*, in which the *uppS* promoter was replaced with a powerful promoter




FIG 2 Bacitracin susceptibility of *B. subtilis* mutants. *B. subtilis* strains 168 (wild type), SC26 (scandium-resistant mutant), and a transformant TI392 (*uppS86*) were grown in L medium at 37°C for 4 h. Cells (approximately 5×10^8 cells/ml) were appropriately diluted with distilled water. Then, aliquots of 2 μ l of cell suspension were spotted onto solid L medium (1.5% agar) containing ZnSO₄ (40 μ g/ml) and bacitracin (+) (100 μ g/ml [7.11 units/ml]), followed by incubation at 37°C for 18 h.




FIG 3 Scandium and bacitracin susceptibilities of various *B. subtilis* strains. *B. subtilis* strains 168, TI392 (*uppS86*), TI408 (P_{S10} -*uppS*), TI403 (*yubB*), TI409 (P_{S10} -*yubB*), and TI393 (*bcrC*) were grown in L medium at 37°C for 4 h. The susceptibilities to scandium (A) and bacitracin (B) were tested as described in the legends to Fig. 1 and 2, except that a scandium concentration of 300 $\mu\text{g/ml}$ was used. wt, wild type.

derived from the S10 ribosomal protein gene cluster (17). During the exponential growth phase, the *uppS* expression level in the resulting strain TI408 (P_{S10} -*uppS*) was approximately 16-fold higher than that in wild-type strain 168 as determined by RT-qPCR analysis (data not shown). As expected, the *uppS*-overexpressing strain TI408 was apparently more susceptible to both scandium and bacitracin (Fig. 3), thus indicating that the increase in free C_{55} -PP results in increased susceptibility.

Effects of *bcrC* and *yubB* disruption on susceptibility. As the reduction in C_{55} -PP phosphatase activity is also thought to result in accumulation of available C_{55} -PP, we next examined whether the disruption of C_{55} -PP phosphatase affects scandium susceptibility. *B. subtilis* possesses at least two C_{55} -PP phosphatases (3). The *bcrC* gene product BcrC, which is similar to the BcrC component of the bacitracin immunity system of *Bacillus licheniformis* (22), has been reported to have C_{55} -PP phosphatase activity (3). In addition, the *yubB* gene product YubB, which is 46% identical to *E. coli* BacA, is also a putative C_{55} -PP phosphatase in *B. subtilis*. We disrupted each of these genes to examine the possible roles of these proteins in scandium susceptibility. As expected, the *bcrC* disruptant mutant TI393 showed higher levels of susceptibility to both scandium and bacitracin (Fig. 3). In contrast, the disruption of *yubB* had no substantial effect on scandium resistance although it slightly decreased the bacitracin resistance. Moreover, the *bcrC yubB* double mutant exhibited the same susceptibility to scandium as the single *bcrC* mutant (data not shown). We assumed that the phosphatase activity of YubB is much lower than that of BcrC. To test this hypothesis, we constructed the *yubB*-overexpressing strain by replacing the *yubB* promoter with an S10 promoter. RT-qPCR analysis showed that the relative amount of *yubB* transcript in the *yubB*-overexpressing strain TI409 (P_{S10} -*yubB*) was 80-fold higher than that in the wild-type strain 168 (data not shown). As expected, overexpression of *yubB* resulted in increased resistance to both scandium and bacitracin (Fig. 3). These results indicate that both BcrC and YubB can function as C_{55} -PP phosphatase in *B. subtilis*.

As the *uppS86* mutation resulted in increased amylase production, we examined whether C_{55} -PP is involved in amylase overproduction. The disruption of *bcrC* or *yubB* stimulated the amylase production to some extent, while the effects of *uppS* or *yubB*




FIG 4 Rare earth element susceptibilities of *B. subtilis* strains. *B. subtilis* strains 168 (wild type), TI392 (*uppS86*), and TI393 (*bcrC*) were grown in L medium at 37°C for 4 h. Then, aliquots of 2 μl of cell suspension were spotted onto rare earth element-free medium (A) and medium containing each rare earth element at the indicated concentration (B to P), followed by incubation at 37°C for 18 h. The rare earth elements used were all chloride salts. Abbreviations: Y, yttrium; La, lanthanum; Ce, cerium; Pr, praseodymium; Nd, neodymium; Sm, samarium; Eu, europium; Gd, gadolinium; Tb, terbium; Dy, dysprosium; Ho, holmium; Er, erbium; Tm, thulium; Yb, ytterbium; Lu, lutetium.

overexpression were marginal (Table 3), thus showing a lack of clear correlation between these gene expression levels and amylase production.

Susceptibilities to other rare earth elements. We examined the effects of the *uppS86* mutation on susceptibilities to other rare earth elements. The mutant TI392 (*uppS86*) was more resistant to ytterbium but not to other rare earth elements tested (Fig. 4). In contrast, the *bcrC* disruption mutant TI393 showed higher susceptibilities to all rare earth elements tested.

DISCUSSION

The ability of bacterial surfaces to bind metal cations has been studied extensively (4). Rare earth elements have also been reported to be accumulated on the cell envelope in both the Gram-positive bacterium *B. subtilis* and the Gram-negative bacterium *E. coli* (2, 30). Recent work clarified that rare earth elements form complexes with multiple phosphate sites at the bacterial cell surface (30). More recently, Moriwaki et al. showed that adsorption

of rare earth ion onto wild-type cell powder was greater than that of lipoteichoic acid-defective strain, suggesting that rare earth ions can be adsorbed to lipoteichoic acid in Gram-positive bacteria (18). Another possible candidate as a rare earth element-binding site on the cell envelope is the carrier lipid precursor C₅₅-PP, which is required for the synthesis of peptidoglycan and a variety of other cell wall polysaccharide components, such as lipopolysaccharides, the enterobacterial common antigen, capsule polysaccharides, and teichoic acids (20, 23, 24, 32, 33). Consistent with these previous studies, we demonstrated that the C₅₅-PP synthase mutation conferred resistance to scandium in *B. subtilis*. Moreover, we found that a mutant lacking the C₅₅-PP phosphatase BcrC was more susceptible to all rare earth elements than the wild-type strain (Fig. 3 and 4). Our findings suggest that the accumulation of C₅₅-PP renders the cell more susceptible to rare earth elements although the mode of action remains unknown. As C₅₅-PP can function as a binding site for rare earth elements on the cell envelope, we propose that the availability of C₅₅-PP is an important determinant of susceptibility to rare earth elements. Although the *uppS86* mutation had no significant effect on resistance to rare earth elements other than scandium and ytterbium, accumulation of available C₅₅-PP is assumed to increase the susceptibility of *B. subtilis* to various rare earth elements.

We found a scandium resistance mutation (*uppS86* mutation) in the *uppS* gene, which encodes C₅₅-PP synthase. This mutation results in a Thr-to-Ile amino acid substitution at residue 86 of the C₅₅-PP synthase. As the forced expression of the wild-type *uppS* gene using a powerful promoter caused increased susceptibility to scandium (Fig. 3A), the *uppS86* mutation appears to be a reduction-of-function mutation. Based on the results of previous structural and mutational analyses of *E. coli* C₅₅-PP synthase (6, 7, 10, 16), residue Thr86 (corresponding to Ser72 in *E. coli* C₅₅-PP synthase) is located in the flexible loop, which is important for catalysis and substrate binding. Deletion of this residue in *E. coli* C₅₅-PP synthase decreases the *k*_{cat} value by 10⁵-fold (6). Accordingly, it is possible that replacement of Thr86 with Ile increased the hydrophobicity of the loop, affecting the enzymatic activity. Interestingly, the corresponding residue in *Saccharomyces cerevisiae* and human dehydrolipoyl pyrophosphate synthases, which catalyze much longer chain elongations than bacterial C₅₅-PP synthases, is originally Ile (9, 27). Although we have no experimental evidence at present, replacement of Thr86 with Ile might affect the chain length of the product.

It is notable that the *uppS86* mutation facilitated amylase production (Table 3). We reported previously that *amyE* expression is activated in the presence of scandium at the late stationary phase, leading to increased production of amylase (12). The *uppS86* mutation conferring scandium resistance, however, did not affect the *amyE* expression level, suggesting that the observed effect of the *uppS86* mutation was exerted at the posttranscriptional level. Thus, the mechanism by which amylase production was stimulated by the *uppS86* mutation is different from that caused by the addition of scandium to the growth medium.

We also demonstrated the roles of BcrC and YubB in scandium resistance; BcrC contributed to resistance to scandium in *B. subtilis* (Fig. 3), while YubB had no significant effect on scandium resistance unless it was overproduced. As the relative expression of *yubB* at the transcriptional level was as high as that of *bcrC* (data not shown), YubB might be negatively regulated at the posttranscriptional level. It is also possible that the C₅₅-PP phosphatase

activity of YubB is much lower than that of BcrC. Further investigation is necessary to clarify the YubB function in *B. subtilis*.

Our results suggest that the accumulation of C₅₅-PP resulted in increased susceptibility to rare earth elements. Although the mechanism by which rare earth elements inhibit the growth of *B. subtilis* remains unclear, accumulation of rare earth elements on the cell envelope may prevent biological function(s) essential for growth.

ACKNOWLEDGMENTS

This work was supported by a grant (to T.I.) from a KAKENHI number 22780078 Grant-in-Aid for Young Scientists (B) and by a grant (to K.O.) from the Effective Promotion of Joint Research of Special Coordination Funds (Ministry of Education, Culture, Sports, Science and Technology of Japan).

We are grateful to the Roche NimbleGen, Inc. (Madison, WI), for supporting the mutation search using the comparative genome sequencing technique.

REFERENCES

1. Apfel CM, Takacs B, Fountoulakis M, Stieger M, Keck W. 1999. Use of genomics to identify bacterial undecaprenyl pyrophosphate synthetase: cloning, expression, and characterization of the essential *uppS* gene. *J. Bacteriol.* 181:483–492.
2. Bayer ME, Bayer MH. 1991. Lanthanide accumulation in the periplasmic space of *Escherichia coli* B. *J. Bacteriol.* 173:141–149.
3. Bernard R, El Ghachi M, Mengin-Lecreux D, Chippaux M, Denizot F. 2005. BcrC from *Bacillus subtilis* acts as an undecaprenyl pyrophosphate phosphatase in bacitracin resistance. *J. Biol. Chem.* 280:28852–28857.
4. Beveridge TJ. 1989. Role of cellular design in bacterial metal accumulation and mineralization. *Annu. Rev. Microbiol.* 43:147–171.
5. Bouhss A, Trunkfield AE, Bugg TD, Mengin-Lecreux D. 2008. The biosynthesis of peptidoglycan lipid-linked intermediates. *FEMS Microbiol. Rev.* 32:208–233.
6. Chang SY, Chen YK, Wang AH, Liang PH. 2003. Identification of the active conformation and the importance of length of the flexible loop 72–83 in regulating the conformational change of undecaprenyl pyrophosphate synthase. *Biochemistry* 42:14452–14459.
7. Chen YH, Chen AP, Chen CT, Wang AH, Liang PH. 2002. Probing the conformational change of *Escherichia coli* undecaprenyl pyrophosphate synthase during catalysis using an inhibitor and tryptophan mutants. *J. Biol. Chem.* 277:7369–7376.
8. El Ghachi M, Bouhss A, Blanot D, Mengin-Lecreux D. 2004. The *bacA* gene of *Escherichia coli* encodes an undecaprenyl pyrophosphate phosphatase activity. *J. Biol. Chem.* 279:30106–30113.
9. Endo S, Zhang YW, Takahashi S, Koyama T. 2003. Identification of human dehydrolipoyl diphosphate synthase gene. *Biochim. Biophys. Acta* 1625:291–295.
10. Guo RT, et al. 2005. Crystal structures of undecaprenyl pyrophosphate synthase in complex with magnesium, isopentenyl pyrophosphate, and farnesyl thiopyrophosphate: roles of the metal ion and conserved residues in catalysis. *J. Biol. Chem.* 280:20762–20774.
11. Inaoka T, Kasai K, Ochi K. 2001. Construction of an in vivo nonsense readthrough assay system and functional analysis of ribosomal proteins S12, S4, and S5 in *Bacillus subtilis*. *J. Bacteriol.* 183:4958–4963.
12. Inaoka T, Ochi K. 2011. Scandium stimulates the production of amylase and bacitracin in *Bacillus subtilis*. *Appl. Environ. Microbiol.* 77:8181–8183.
13. Inaoka T, Satomura T, Fujita Y, Ochi K. 2009. Novel gene regulation mediated by overproduction of secondary metabolite neotrehalosadiamine in *Bacillus subtilis*. *FEMS Microbiol. Lett.* 291:151–156.
14. Itaya M, Kondo K, Tanaka T. 1989. A neomycin resistance gene cassette selectable in a single copy state in the *Bacillus subtilis* chromosome. *Nucleic Acids Res.* 17:4410.
15. Kawai K, Wang G, Okamoto S, Ochi K. 2007. The rare earth, scandium, causes antibiotic overproduction in *Streptomyces* spp. *FEMS Microbiol. Lett.* 274:311–315.
16. Ko TP, et al. 2001. Mechanism of product chain length determination and the role of a flexible loop in *Escherichia coli* undecaprenyl-pyrophosphate synthase catalysis. *J. Biol. Chem.* 276:47474–47482.
17. Li X, Lindahl L, Sha Y, Zengel JM. 1997. Analysis of the *Bacillus subtilis* S10 ribosomal protein gene cluster identifies two promoters that may be

- responsible for transcription of the entire 15-kilobase S10-*spc*- α cluster. J. Bacteriol. 179:7046–7054.
18. Moriwaki H, Koide R, Yoshikawa R, Warabino Y, Yamamoto H. 12 June 2012, posting date. Adsorption of rare earth ions onto the cell walls of wild-type and lipoteichoic acid-defective strains of *Bacillus subtilis*. Appl. Microbiol. Biotechnol. doi:10.1007/s00253-012-4200-3.
 19. Moriya S, et al. 1998. A *Bacillus subtilis* gene-encoding protein homologous to eukaryotic SMC motor protein is necessary for chromosome partition. Mol. Microbiol. 29:179–187.
 20. Neuhaus FC, Baddiley J. 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67:686–723.
 21. Ohashi Y, Ohshima H, Tsuge K, Itaya M. 2003. Far different levels of gene expression provided by an oriented cloning system in *Bacillus subtilis* and *Escherichia coli*. FEMS Microbiol. Lett. 221:125–130.
 22. Ohki R, et al. 2003. A bacitracin-resistant *Bacillus subtilis* gene encodes a homologue of the membrane-spanning subunit of the *Bacillus licheniformis* ABC transporter. J. Bacteriol. 185:51–59.
 23. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71:635–700.
 24. Reeves PR, et al. 1996. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. 4:495–503.
 25. Rogers HJ, Syngé C, Woods VE. 1980. Antibacterial effect of scandium and indium complexes of enterochelin on *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. 18:63–68.
 26. Rogers HJ, Woods VE, Syngé C. 1982. Antibacterial effect of the scandium and indium complexes of enterochelin on *Escherichia coli*. J. Gen. Microbiol. 128:2389–2394.
 27. Sato M, Fujisaki S, Sato K, Nishimura Y, Nakano A. 2001. Yeast *Saccharomyces cerevisiae* has two *cis*-prenyltransferases with different properties and localizations. Implication for their distinct physiological roles in dolichol synthesis. Genes Cells 6:495–506.
 28. Stone KJ, Strominger JL. 1971. Mechanism of action of bacitracin: complexation with metal ion and C₅₅-isoprenyl pyrophosphate. Proc. Natl. Acad. Sci. U. S. A. 68:3223–3227.
 29. Storm DR, Strominger JL. 1973. Complex formation between bacitracin peptides and isoprenyl pyrophosphates. The specificity of lipid-peptide interactions. J. Biol. Chem. 248:3940–3945.
 30. Takahashi Y, Yamamoto M, Yamamoto Y, Tanaka K. 2010. EXAFS study on the cause of enrichment of heavy REEs on bacterial cell surfaces. Geochim. Cosmochim. Acta 74:5443–5462.
 31. Tanaka Y, Hosaka T, Ochi K. 2010. Rare earth elements activate the secondary metabolite-biosynthetic gene clusters in *Streptomyces coelicolor* A3(2). J. Antibiot. (Tokyo) 63:477–481.
 32. van Heijenoort J. 2001. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod. Rep. 18:503–519.
 33. Wicken AJ, Knox KW. 1980. Bacterial cell surface amphiphiles. Biochim. Biophys. Acta 604:1–26.
 34. Wurm M. 1951. The effect of lanthanum on growth and metabolism of *Streptococcus faecalis* R. J. Biol. Chem. 192:707–714.